Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 7 (July)

1. The X factor: skewing X inactivation towards cancer.
   Cell, 129(7): 1253-4. [Abstract] [Full-text]
2. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.
   J Clin Oncol, 25(19): 2656-63. [Abstract] [Full-text]
3. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
   J Clin Oncol, 25(19): 2678-84. [Abstract] [Full-text]
4. HER2 gene status in primary breast cancers and matched distant metastases.
   Breast Cancer Res, 9(3): R31. [Abstract] [Full-text]
5. HER2 status in breast cancer--an example of pharmacogenetic testing.
   J R Soc Med, 100(7): 326-9. [Abstract] [Full-text]
6. A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
   Clin Cancer Res, 13(13): 3989-98. [Abstract] [Full-text]
7. Gene expression profiling in sarcomas.
   Crit Rev Oncol Hematol, 63(2): 111-24. [Abstract] [Full-text]
8. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
   Mol Cancer Ther, 6(7): 2065-72. [Abstract] [Full-text]
9. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
   Mol Cancer Ther, 6(7): 1973-82. [Abstract] [Full-text]
10. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.
    J Steroid Biochem Mol Biol. [Abstract] [Full-text]
11. Predictive medicine: incipient reality or fata morgana?
    J Pathol, 212(4): 353-5. [Abstract] [Full-text]
12. Molecular targeted therapies in breast cancer: Where are we now?
    Int J Biochem Cell Biol, 39(7): 1375-87. [Abstract] [Full-text]
13. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.
    Int J Gynecol Cancer, 17(4): 739-63. [Abstract] [Full-text]
14. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
    Cell Prolif, 40(4): 488-507. [Abstract] [Full-text]
15. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.
    BMC Cancer, 7: 110. [Abstract] [Full-text]
16. Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type.
    Hum Cell, 20(3): 85-90. [Abstract] [Full-text]
17. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Cancer, 110(3): 489-98. [Abstract] [Full-text]
18. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
    J Control Release, 120(3): 169-77. [Abstract] [Full-text]
19. The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations.
    Curr Treat Options Oncol. [Abstract] [Full-text]
20. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    J Clin Oncol, 25(22): 3246-50. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.